Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials For the primary endpoint, 25.4% of children ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Once-daily roflumilast cream at 0.15% improved symptoms of atopic dermatitis (AD) across multiple end points. According to investigators of the phase 3 studies that uncovered the findings, roflumilast ...

Arcutis Biotherapeutics has announced promising results from its Phase 3 INTEGUMENT-OLE study concerning the investigational ZORYVE cream for treating atopic dermatitis (AD). The long-term study ...

Full data results will be presented at future medical conferences and in peer-reviewed journals. The INTEGUMENT-1 study met the primary endpoint and all secondary endpoints. Topline results were ...

ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks Caregivers reported rapid improvement in itch in as ...

Roflumilast cream 0.05% showed durable efficacy and long-term tolerability in children aged 2 to 5 years with atopic dermatitis over 56 weeks. The cream demonstrated high application-site tolerability ...

Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older. Roflumilast cream 0.15% is a ...